Ken Griffin Xencor Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.7 - $21.65 $21,980 - $30,309	-1,400 Reduced 35.9%	2,500 $50,000
Q2 2024 Aug 14, 2024	BUY	$18.21 - $24.5 $30,957 - $41,650	1,700 Added 77.27%	3,900 $73,000
Q1 2024 May 15, 2024	BUY	$18.65 - $26.52 $7,459 - $10,608	400 Added 22.22%	2,200 $48,000
Q4 2023 Feb 14, 2024	BUY	$16.53 - $21.42 $21,489 - $27,846	1,300 Added 260.0%	1,800 $38,000
Q3 2023 Nov 14, 2023	SELL	$20.08 - $25.39 $16,063 - $20,312	-800 Reduced 61.54%	500 $10,000
Q1 2023 May 15, 2023	BUY	$25.95 - $36.95 $28,545 - $40,645	1,100 Added 550.0%	1,300 $36,000
Q4 2022 Feb 14, 2023	BUY	$24.79 - $30.86 $4,958 - $6,172	200 New	200 $5,000

215

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.38B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.